Sunshine Guojian Pharmaceutical Shanghai Co Ltd. Stock Analysis 688336.SS

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. engages in the development and manufacture of biopharmaceutical focused on antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 1,012 full-time employees. The company went IPO on 2020-07-22. The firm focuses on the research of new technologies such as monoclonal antibodies, bispecific antibodies, polyspecific antibodies and multifunctional recombinant proteins. The firm's main products include Yisaipu (recombinant human type II tumor necrosis factor receptor-antibody fusion protein), Saiputing (Initutumab for injection) and Jiannipa (recombinant anti-CD25 humanized monoclonal antibody injection). The firm's products are mainly used in the fields of breast cancer, rheumatism and autoimmune diseases. The firm mainly operates its businesses in the domestic and overseas markets.